Addiction Medicine Email List | 42,318 Verified Contacts | SparkDBi
An addiction medicine email list is a verified database of licensed addiction medicine physicians, addiction psychiatrists, buprenorphine-waivered providers, opioid treatment program (OTP) medical directors, and substance use disorder specialists. SparkDBi maintains 42,318 verified US addiction medicine contacts across 12 provider types, sourced from conference and CME partnerships, federal OTP program directories, state medical licensing records, and B2B2C matching programs.
Trusted by 2,600+ world-class brands and organizations
The opioid epidemic has created a sharply segmented addiction medicine prescriber landscape. Office-based opioid treatment (OBOT) providers who can prescribe buprenorphine directly, federally licensed opioid treatment programs (OTPs) that dispense methadone, addiction psychiatrists managing co-occurring mental health and SUD, and community-based recovery programs each require different outreach strategies. SparkDBi segments all 42,318 verified addiction medicine contacts by provider type, treatment setting, and certification status so pharma and device teams can reach the right prescribers with the right message.
The 2023 SUPPORT Act removed the federal X-waiver requirement for buprenorphine prescribing, expanding the eligible prescriber pool from roughly 110,000 waivered providers to any DEA Schedule III-registered practitioner. This has changed the outreach calculation: the target is no longer a narrow waivered list but a broader segment of primary care, internal medicine, and emergency physicians who may now prescribe buprenorphine but have not yet integrated MAT into practice.
How Addiction Medicine Prescribers Are Classified
Addiction medicine sits across four distinct certification and practice pathways, each with different NPI taxonomy codes and outreach implications.
ABAM/ABPM board-certified addiction medicine physicians are the core specialist group. The American Board of Addiction Medicine (ABAM) and the American Board of Preventive Medicine (ABPM) both issue addiction medicine certification. This group, roughly 7,000 physicians nationally, represents the highest-value target for MAT drug programs because they treat the highest volumes of patients with opioid and alcohol use disorder.
Addiction psychiatrists hold dual board certification in psychiatry (ABPN) and addiction psychiatry. They manage patients with co-occurring psychiatric conditions and SUD. Addiction psychiatrists are distinct from addiction medicine physicians; they carry a different NPI taxonomy code and are typically found in academic medical centers, hospital-based programs, and specialty behavioral health settings.
Primary care MAT providers are family medicine and internal medicine physicians who have incorporated buprenorphine prescribing into standard practice. Post-X-waiver elimination, this is the fastest-growing prescriber segment. SparkDBi flags primary care physicians with MAT program integration separately from general primary care lists.
OTP medical directors oversee federally licensed methadone treatment programs. Approximately 1,900 federally licensed OTPs operate nationally. OTP directors are a small but high-influence prescriber segment for programs targeting methadone augmentation therapies and OTP operational products.
What Companies Use the Addiction Medicine Email List
Pharmaceutical companies with MAT drug programs account for the majority of buyers. Buprenorphine is the highest-volume category, with multiple formulations competing for prescriber adoption: Suboxone (film), Subutex, Sublocade (monthly injectable), and generic buprenorphine/naloxone combinations. Each formulation targets a different prescriber behavior - clinic-administered injectable programs require different outreach than take-home sublingual film programs.
Extended-release naltrexone (Vivitrol) programs target addiction medicine physicians and primary care MAT providers managing alcohol use disorder and patients who are fully opioid-detoxed. Alcohol use disorder is a secondary but growing outreach category: acamprosate, disulfiram, and new GABAergic compounds in clinical trials all require addiction medicine and primary care physician outreach.
Medical device and digital health companies have entered the addiction medicine market through remote patient monitoring for MAT adherence, urine drug screen platforms, and digital therapeutic applications for SUD. These companies need addiction medicine physician contacts for clinical partnership programs and product adoption outreach.
| Buyer | How They Use the Addiction Medicine List |
|---|---|
| Pharma - buprenorphine program | Addiction medicine specialists and primary care MAT providers for buprenorphine product outreach, filtered by OBOT vs OTP setting and practice volume |
| Pharma - naltrexone (AUD/OUD) | Addiction psychiatrists and addiction medicine physicians for extended-release naltrexone outreach targeting alcohol use disorder and post-detox OUD maintenance programs |
| Medical device - remote monitoring | Addiction medicine program directors and OTP medical directors for MAT adherence monitoring platform partnerships and clinical evaluation outreach |
| Digital health - SUD platform | Addiction medicine physicians and behavioral health NPs for digital therapeutic SUD program clinical partnership outreach and prescription app integration |
| Payer / health plan | Addiction medicine specialists for value-based care SUD program recruitment, HEDIS measure engagement, and opioid safety initiative outreach |
Request Addiction Medicine Contact Data
Provider type filters, treatment setting, waiver status - sample records available
Addiction Medicine Provider Types and Verified Contacts
The SparkDBi addiction medicine database covers 12 provider types. The table below shows all segments by verified contact count. Contacts can be delivered as a combined list or as individual provider-type segments.
| Provider Type | Classification | Contacts |
|---|---|---|
| Addiction Medicine Specialist | Physician | 8,340 |
| Nurse Practitioner - Substance Use Disorder | Nurse | 7,840 |
| Registered Nurse - Addiction | Nurse | 5,420 |
| Licensed Clinical Social Worker - SUD | Behavioral Health | 4,280 |
| Family Medicine - Addiction | Physician | 4,180 |
| Physician Assistant - Addiction Medicine | PA | 3,840 |
| Internal Medicine - Addiction | Physician | 2,890 |
| Clinical Nurse - Addiction | Nurse | 2,180 |
| Addiction Psychiatrist | Physician | 1,842 |
| Psychologist - Addiction | Behavioral Health | 890 |
| Preventive Medicine - Addiction | Physician | 350 |
| OTP Medical Director | Physician | 266 |
All 12 provider types. Total: 42,318 verified contacts.
Key Drugs, Devices, and Treatment Categories
Opioid use disorder (OUD) is the highest-volume treatment area. Buprenorphine-based medications (Suboxone, Subutex, Sublocade, Brixidi) are the dominant outpatient MAT option. Methadone is exclusively dispensed through OTP-licensed programs. Extended-release naltrexone (Vivitrol) is the primary option for fully detoxed patients. Lofexidine (Lucemyra) is used for opioid withdrawal management. The FDA approval of Brixidi (buprenorphine weekly and monthly subcutaneous injectable) in 2023 created a new outreach segment targeting addiction medicine physicians willing to adopt clinic-administered long-acting formulations.
Alcohol use disorder (AUD) is treated with naltrexone oral (ReVia, generics), extended-release naltrexone injectable (Vivitrol), acamprosate (Campral), and disulfiram (Antabuse). New mechanisms including GABA-B agonists and GLP-1 receptor agonists for alcohol craving reduction are in late-stage trials and will drive addiction medicine outreach activity in 2026-2028.
Stimulant use disorder has no FDA-approved pharmacotherapy but is a growing clinical focus. Contingency management programs, extended-release mixed amphetamine salts (off-label for methamphetamine use disorder in research settings), and bupropion-naltrexone combination studies are active areas that require addiction medicine physician engagement.
Digital therapeutics for SUD include reSET and reSET-O (Pear Therapeutics), Connections (Volpicelli at Penn), and several apps targeting CBT-based SUD treatment. These platforms need addiction medicine physician advocates and clinical partnership contacts for adoption outreach.
How SparkDBi Sources and Verifies Addiction Medicine Contacts
SparkDBi builds its addiction medicine database from multiple vetted sources. Primary inputs include federal substance use treatment program directories, state medical board licensure records, national addiction medicine association conference attendance records, CME event participation from addiction medicine education platforms, and B2B2C data matching programs.
CMS and NPPES data is used as a cross-reference only, not a primary source. NPPES records for addiction medicine providers are frequently stale, particularly for community-based and federally qualified health center providers who have higher practice turnover than hospital-employed specialists.
Verification runs across three layers: email inbox confirmation (direct server verification without sending), active phone number validation, and physical practice address confirmation. Records that fail any verification layer are removed and replaced in the monthly refresh cycle.
NPI Taxonomy Codes for Addiction Medicine
CMS NPI taxonomy codes for addiction medicine provider types. These are used to specify segment requirements and independently verify provider credentials against NPPES records.
| Taxonomy Code | Classification |
|---|---|
| 207LA0401X | Addiction Medicine - Family Medicine |
| 2084A2900X | Addiction Medicine - Psychiatry |
| 2080A0000X | Addiction Medicine - Preventive Medicine |
| 207QA0401X | Addiction Medicine - General Practice |
| 2084P0804X | Addiction Psychiatry |
Practice Setting Breakdown
Addiction medicine providers work across a broader range of settings than most specialties. Approximately 28% of SparkDBi addiction medicine contacts practice in office-based outpatient settings (private practice, group practice, or federally qualified health centers). Hospital-employed or academic addiction medicine programs account for 22%. Community mental health centers and behavioral health organizations account for 31%. OTP-licensed methadone programs represent approximately 8%. The remaining 11% are in correctional, residential treatment, or telehealth-only settings.
Setting matters for outreach strategy. FQHC-based providers have different formulary dynamics than private practice MAT providers. Hospital-based addiction consult services require different messaging from outpatient OUD programs. SparkDBi can segment by practice setting for campaigns where setting type affects the clinical message.
Leading Addiction Medicine Treatment Centers
The institutions below are among the largest and most cited addiction medicine programs in the US. SparkDBi covers physicians and clinical staff at these and comparable institutions nationwide.
| Rank | Institution | Location |
|---|---|---|
| 1 | McLean Hospital | Belmont, MA |
| 2 | Hazelden Betty Ford Foundation | Center City, MN |
| 3 | Johns Hopkins Bayview Addiction Treatment Services | Baltimore, MD |
| 4 | Boston Medical Center Opioid Treatment Program | Boston, MA |
| 5 | Yale School of Medicine CSAT Program | New Haven, CT |
| 6 | UCSF Department of Addiction Medicine | San Francisco, CA |
| 7 | Rush University Medical Center - Behavioral Health | Chicago, IL |
| 8 | Sheppard Pratt Addiction Medicine | Baltimore, MD |
| 9 | University of Washington ADAI | Seattle, WA |
| 10 | Columbia University Medical Center SUD Program | New York, NY |
State-by-State Coverage
The SparkDBi addiction medicine database covers all 50 states. Highest concentrations are in California, New York, Texas, Florida, and Pennsylvania, tracking opioid overdose mortality data and state-level MAT program investment. Massachusetts has a disproportionately high contact density relative to population due to its early and sustained investment in addiction medicine infrastructure.
| State | Verified Contacts |
|---|---|
| California | 5,840 |
| New York | 4,620 |
| Texas | 3,890 |
| Florida | 3,210 |
| Pennsylvania | 2,780 |
| Massachusetts | 2,540 |
| Ohio | 2,180 |
| Illinois | 1,920 |
| Michigan | 1,650 |
| New Jersey | 1,440 |
International addiction medicine contacts are available for Canada, the UK, and Australia. Contact SparkDBi for current counts by country.
Deliverability Notes
Addiction medicine providers in private practice, FQHC, and community mental health settings show variable email filtering depending on network infrastructure. FQHC and community mental health email environments often use managed healthcare IT providers with stricter filtering than private practice domains. SparkDBi flags enterprise vs. independent email domains in delivered datasets so buyers can adjust sending strategy for each segment.
Data Enrichment and Available Fields
For existing addiction medicine contact lists, SparkDBi can append or verify: NPI numbers, provider type classification, practice setting, email addresses, practice addresses, phone numbers, and license status. Match rates average 71% against the full SparkDBi database.
Compliance
The SparkDBi addiction medicine email list contains no patient data. All records are professional contact information for licensed providers. The database is HIPAA-aligned, CAN-SPAM compliant, and CCPA-aware. Business Associate Agreements are available on request.